3 cheap FTSE 100 stocks to buy and hold for 10 years 

These FTSE 100 stocks are not the cheapest, but they are cheaper than many other index constituents. And they have also given great returns over time. 

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Cheap stocks are getting incredibly hard to come by among FTSE 100 constituents. As the stock markets stay buoyant, share prices are rising fast too. But there are still some stocks that can be seen as relatively cheap. To figure out which ones these are, I first consider the price-to-earnings (P/E) ratio for the FTSE 100 index as a whole. This is around 20 times. 

Many of the stocks that are performing well right now have P/Es well over this level. But there are some around that have lower P/Es too. This is important, because it suggests that these stocks could be undervalued compared to the average FTSE 100 stock. This in turn means that their share prices could rise in the near future. 

Hikma Pharmaceuticals: beaten down FTSE 100 stock

One such stock is the pharmaceuticals company Hikma Pharmaceuticals. It has a P/E of 15.2 times, which is not terribly low, but is still lower than average. This leaves some room for growth. But I believe that there could be even more upside considering that it has just delivered robust results.

Moreover, its share price has come off in the past year. As I write, it is down by more than 12% from the same time last year. I think this is a good reason to buy the stock, which has given some 300% return over the last 10 years, albeit with a fair bit of fluctuation in the intervening period. It is definitely a stock on my wish list right now. 

Persimmon: attractive dividend yields

The FTSE 100 house builder Persimmon has a similar story. It has a relatively low P/E of 11.2 times, at least partly because its share price has gone nowhere in the past year. In fact, it has shown a small decline. But over the past decade, it has been an excellent stock to hold. It has grown by more than 500% over this time! And here is another good bit: it also has an attractive dividend yield of 6.5%.

The outlook for property stocks is a bit iffy for next year considering that supportive government policies are being withdrawn. Yet, over the long term, I think this is a winning stock, even if it sees ups and downs during the course of the business cycle. I bought the stock for the long term for this reason a few months ago. 

3i: impressive returns

Last is the investment company 3i, which has given the best returns among the three stocks in consideration here, of almost 700% over the last 10 years. It has also risen some 30% over the past year, though its P/E remains low at 4.5 times. If I consider its price to net asset value, the more popular indicator for measuring investment companies’ value, it does appear a bit overvalued.

Still, it recently delivered good results and is also optimistic about the future, which suggests to me that at a buoyant time for the stock markets, its share price could continue to rise. The stock is a buy for me.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Manika Premsingh owns shares of Persimmon. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »